What is High Q Technologies?
Founded in 2013, High Q Technologies operates at the intersection of quantum physics and life sciences. The company specializes in the development of patented quantum devices and control techniques for EPR spectroscopy, providing structural biologists with the sensitivity and stability required to map complex protein interactions. Their flagship instruments are engineered to replace legacy, cumbersome hardware with intuitive, compact, and fully automated systems. By streamlining the data acquisition process, High Q Technologies enables researchers to resolve historically intractable problems in protein dynamics, thereby shortening the development cycle for novel therapeutics and enhancing the efficacy of drug discovery pipelines.
How much funding has High Q Technologies raised?
High Q Technologies has raised a total of $3.8M across 1 funding round:
Grant
$3.8M
Grant (2024): $3.8M with participation from Government of Canada
Key Investors in High Q Technologies
Government of Canada
The Government of Canada acts as a primary public sector stakeholder, providing strategic grants and support to foster innovation and technological advancement within the Canadian biotech and quantum research sectors.
What's next for High Q Technologies?
Looking ahead, the strategic deployment of the $3.8M will likely focus on expanding the commercial footprint of High Q Technologies' EPR platforms. As the company transitions from a research-heavy development phase to a broader enterprise-level commercialization strategy, the focus will shift toward increasing manufacturing capacity and deepening integration with high-throughput screening environments. The firm is expected to leverage its unique quantum sensing capabilities to capture a larger share of the structural biology market, potentially establishing new industry standards for speed and precision in protein analysis. Continued investment in software automation and user-interface refinement will remain central to their growth trajectory as they scale operations to meet the demands of global biopharmaceutical partners.
See full High Q Technologies company page
